

Supplementary file 2: Table. Clinical course of SARS-CoV-2-positive patients				
Clinical course No.(%)	Total (N=25)	Mild (N=12)	Moderate (N=12)	Severe/Critically ill (N=1)
Female	13 (52%)	7 (58.33%)	5 (41.67%)	1 (100%)
Male	12 (48%)	5 (41.67%)	7 (58.33%)	0 (0%)
Age group No.(%)	25 (100%)	12 (100%)	12 (100%)	1 (100%)
≤5 years	17(68%)	8 (66.67%)	9 (75%)	0 (100%)
6-11 years	6 (24%)	4 (33.33%)	1 (8.33%)	1 (100%)
12-18 years	2 (8%)	0 (0%)	2 (16.67%)	0 (0%)
Hospitalization No.(%)	25 (100%)	12 (100%)	12 (100%)	1 (100%)
Yes	7 (28%)	0 (0%)	6 (50%)	1 (100%)
No	18 (72%)	12 (100%)	6 (50%)	0 (0%)
Hospital unit No.(%)	7 (28%)	0 (0%)	6 (50%)	1 (100%)
Pediatric unit	5 (20%)	0 (0%)	5 (41.67%)	0 (0%)
ICU	2 (8%)	0 (0%)	1 (8.33%)	1 (100%)
Type of treatment No.(%)	25 (100%)	5 (41.67%)	12 (100%)	1 (100%)
IV antibiotics	9 (36%)	2 (16.67%)	6 (50%)	1 (100%)
IV steroids	10 (40%)	0 (0%)	9 (75%)	1 (100%)
IV liquids	12 (48%)	2 (16.67%)	9 (75%)	1 (100%)
Beta-2 agonists	6 (24%)	0 (0%)	5 (41.67%)	1 (100%)
Oxygen therapy	3 (12%)	0 (0%)	2 (16.67%)	1 (100%)
Antihistamines	8 (32%)	2 (16.67%)	6 (50%)	0 (0%)
Antiparasitic	1 (4%)	1 (8.33%)	0 (0%)	0 (0%)
None	7 (28%)	7 (58.33%)	0 (0%)	0 (0%)
Treatment days No.(%)	25 (100%)	12 (100%)	12 (100%)	1 (100%)
No treatment	7 (28%)	7 (58.33%)	0 (0%)	0 (0%)
0-7 days	2 (8%)	1 (8.33%)	1 (8.33%)	0 (0%)
8-14 days	14 (56%)	2 (16.67%)	11 (91.67%)	1 (100%)
≥ 15 days	2 (8%)	2 (16.67%)	0 (0%)	0 (0%)
Coinfection (Bacteria) No.(%)	25 (100%)	12 (100%)	12 (100%)	1 (100%)
Yes	2 (8%)	0 (0%)	2 (16.67%)	0 (0%)
No	23 (92%)	0 (0%)	10 (83.33%)	0 (0%)
Comorbidities No.(%)	25 (100%)	12 (100%)	12 (100%)	1 (100%)
No	10 (40%)	6 (46.15%)	3 (25%)	1 (100%)
Yes	15 (60%)	6 (46.15%)	9 (75%)	0 (0%)